The EADO is an independent non-profit organization dedicated to
  • promote
  • coordinate   and
  • improve
clinical and laboratory research activities in the field of skin cancer including primary and secondary prevention, early detection, clinical diagnosis and clinical and experimental research.


Ongoing Studies

  • A multicenter, randomized, double-blind study of dacarbazine with or without
    Genasense® in chemotherapy-naïve subjects with advanced melanoma and low LDH
  • Randomized, multicenter phase III trial comparing adjuvant treatment with Peglntron 36 months versus Intron A over 18 months in melanoma AJCC stage II patients. 6/03 - 6/08.

    •  PEG Intron, Study Synopsis
     Recruitement PEG Intron


  • Randomized, multicenter, open label study to compare the efficiency and tolerability of pegylated-a-2a (PEG-IFN) to “low dose” interferon-a-2a in patients with malignant melanoma in stages IIA (T3a) – IIIB (AJCC-2002), Sister Society ADO multicenter trial Germany, Switzerland, Austria. start 8/2004-

    •

HOME